Tapinarof is a first-in-class, steroid-free topical cream approved for adults with plaque psoriasis. It targets the aryl hydrocarbon receptor (AHR), which plays a key role in regulating immune and skin cell responses. Tapinarof reduces skin inflammation, oxidative stress, and helps restore the skin barrier. By binding to AHR, it suppresses IL-17A transcription, resulting in an anti-inflammatory effect. Additionally, Tapinarof activates the AHR-Nrf2 pathway, providing antioxidant protection and promoting skin health. This innovative approach offers a new treatment option for managing plaque psoriasis.